Estrella Immunopharma Overview
Latest P/E ratio for Estrella Immunopharma: -2.94 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-2.94
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Estrella Immunopharma's p/e ratio stands at -2.94. That is below the sector sector average of 47.3. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Estrella Immunopharma sits lower the its sector benchmark (47.3) with a P/E ratio of -2.94. That is roughly 106.2% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether -2.94 is attractive depends on Estrella Immunopharma's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Estrella Immunopharma's P/E ratio evolved across reporting periods, while the comparison chart places ESLA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
